



15 July 2022

## ASX ANNOUNCEMENT

### **New Heart Failure Data Evaluating ImpediMed's SOZO® in Heart Failure Patients to be Presented at Heart Failure Society of America Annual Scientific Meeting 2022**

ImpediMed Limited (ASX:IPD) is pleased to announce that two abstracts evaluating use of ImpediMed's SOZO® Digital Health Platform in heart failure patients were accepted for poster presentation at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022 on 30 September to 3 October in Washington D.C., USA.

The abstracts are titled:

- Bioimpedance Spectroscopy Distinguishes between Fluid Status in Individuals with and without Heart Failure
- Bioimpedance Spectroscopy Derived Arm-to-Leg R0\_ratio as a Predictor of Increased Intravascular Volume and Need for Up-Dosing

The HFSA Annual Meeting draws experts on heart failure care with the goal of reducing the burden of heart failure through education, innovation, and research. It is a highly specialised scientific conference and one of the leading forums to present research in heart failure.

"Inaccuracies of clinical assessments have plagued the estimation of volume in HF patients. This work examines the use of BIS as an objective measure of volume overload to help predict congestion and potentially guide medical intervention." commented Dr. Andrew Accardi, Emergency Medicine Physician at Scripps Health in San Diego, California and author on both posters.

"The HFSA annual meeting is the premier forum to present data on new technologies and innovations in heart failure," stated Richard Carreon, Managing Director and CEO of ImpediMed. "Presenting data here reinforces ImpediMed's commitment to innovation and research into improving care for heart failure patients. The visibility and connections made during these meetings supports our commercialisation effort in heart failure."

The Heart Failure Society of America is a multidisciplinary organisation working to improve and expand heart failure care through collaboration, education, research, innovation, and advocacy. HFSA members include physicians, scientists, nurses, nurse practitioners, pharmacists, and patients. HFSA is recognised as a clearinghouse for information on heart failure research including drugs, devices, and patient care. HFSA jointly develops guidelines for the management of heart failure with the American College of Cardiology and American Heart Association.

**Approved for release by the Managing Director and CEO, Mr. Richard Carreon.**

## Contact Details

### Investor Relations Contact:

Mike Bassett, ImpediMed  
SVP Corporate and Strategic Development  
T: +61 407 431 432  
E: [mbassett@impedimed.com](mailto:mbassett@impedimed.com)

### About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition sold in select markets globally.

[Click here for more information on ImpediMed](#)

### About SOZO Digital Health Platform

SOZO, the world's most advanced, noninvasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed's BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire Healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphedema, provides fluid status for patients living with heart failure, and can be used to monitor and maintain overall health – all on a single device.

For more information, visit: <https://www.impedimed.com/products/sozo/>.

### About SOZO Fluid Analysis for Heart Failure

The SOZO fluid analysis for heart failure provides an objective measure of fluid volume in heart failure patients. It utilises ImpediMed's HF-Dex™ heart failure index, to help clinicians identify the optimal fluid volume range for their patients. HF-Dex is presented on BIS-derived reference ranges which indicate normal fluid volumes and elevated fluid volumes, which may require further clinical investigation.

The abstracts accepted for poster presentation falls outside of the current FDA clearances for SOZO and HF-Dex™.

For more information, visit:

[https://www.impedimed.com/specialty/cardiology/?utm\\_source=branded&utm\\_medium=us\\_news\\_release&utm\\_campaign=hfsa\\_poster\\_sozo\\_heart-failure&utm\\_campaign-id=&utm\\_term=&utm\\_content=text-link\\_specialty\\_cardiology](https://www.impedimed.com/specialty/cardiology/?utm_source=branded&utm_medium=us_news_release&utm_campaign=hfsa_poster_sozo_heart-failure&utm_campaign-id=&utm_term=&utm_content=text-link_specialty_cardiology)

### **Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

For personal use only